The companies have initiated a research agreement supporting the development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis.
https://www.pharmalive.com/wp-content/uploads/2022/12/Anumana-logo.jpg400700Administratorhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAdministrator2022-12-15 14:50:162022-12-15 14:50:16Anumana and Pfizer partner to enable early detection of underdiagnosed cardiovascular disease
